GlaxoSmithKline (GSK) has agreed to acquire Affinivax, a Boston-based clinical-stage vaccine developer, in a deal worth up to $3.3 billion. The consideration includes an upfront payment of $2.1 billion and payments of up to $1.2 billion based on potential development milestones. Affinivax is engaged in developing vaccines by using its Multiple Antigen Presenting System (MAPS) […]
Novus Therapeutics has launched a phase 1 pharmacodynamics clinical trial for its promising candidate, OP0201, aimed at treating otitis media—a common middle ear infection. The California-based specialty pharmaceutical company, known for its focus on ENT (ear, nose, and throat) disorders, has begun dosing the first adult patients in the trial, named OP0201-C-001, which is taking […]
